TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin Versus Placebo in Patients With Neutropenia and Fever

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients in the above categories who are currently undergoing chemotherapy.~2. Patients at least 18 of age.~3. Patient expected to reach an absolute granulocyte count of \<100 cells/mm3~4. Patients who have given written consent because of the above criteria must have at least one temperature of greater or equal to 38.3° or temperatures \> 38o on at least two occasions before study drug is administered.~Exclusion Criteria:~1. Patients with lymphoma or with solid tumor undergoing initial chemotherapy. Their neutropenia is of insufficient duration for adequate test of the value of an anti-gram positive antibiotic.~2. Patients undergoing auto-transplantation, for the same reason as above.~3. Patients with evidence of a clinical infection such as presence of a pulmonary infiltrate by x-ray or clinical evidence for the presence of cellulitis.~4. Patients who have received daptomycin in the two weeks prior to enrollment.~5. Patients with concomitant use of vancomycin.~6. Patients with creatinine clearance \< 30 ml/min or CPK \> 3x normal~7. Patients with significant hepatic dysfunction, defined as baseline liver function tests \> 5x above normal.~8. Patients with known allergy to daptomycin.~9. Patients previously in this study.~10. Women of child bearing age who are either lactating or pregnant (as evidenced by a positive urine pregnancy test or positive serum beta-HCG).~11. Patients previously enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daptomycin (Type: ACTIVE_COMPARATOR): Daptomycin intravenous 8mg/kg once per day 5-10 days.
- Saline Placebo (Type: PLACEBO_COMPARATOR): Saline solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tacrolimus to Sirolimus Conversion for Delayed Graft Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age =\> 18.~2. Recipient of a deceased donor kidney transplant.~3. Delayed graft function, defined as need for dialysis during first week after surgery or slow graft function, defined as creatinine \>=3.0 by post-op day 5 without requiring dialysis~4. Stable serum creatinine for 2 weeks prior to enrollment.~5. Able to give informed consent.~6. Compliant with medical regimen and clinic visits.~Exclusion Criteria:~1. Episode of acute rejection within 4 weeks prior to enrollment.~2. Calculated GFR \< 30 ml/min.~3. Interstitial fibrosis \& tubular atrophy in transplant biopsy higher than grade II (Banff05 update).~4. Proteinuria \> 500 mg/24 h or spot urine protein/creatinine \> 0.5.~5. Total fasting cholesterol level \> 300 mg/dl or triglyceride \> 500 mg/dl despite optimal lipid lowering therapy.~6. Recipient of pancreas or liver allografts.~7. Leukopenia (WBC \< 3000 mm3) within 2 weeks prior to enrollment.~8. Leukopenia (WBC \< 2000 mm3) within 4 weeks prior to enrollment.~9. Thrombocytopenia (platelets count \< 100,000/mm3) within 2 weeks prior to enrollment.~10. Unwilling to comply with study protocol.~11. Enrollment in another drug trial that precludes use of sirolimus.~12. Diagnosis of malignancy within 2 years prior to enrollment, except adequately treated non-melanoma skin cancer.~13. For women, pregnancy.~14. Allergy to iodine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus (Type: ACTIVE_COMPARATOR): Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
- Sirolimus (Type: ACTIVE_COMPARATOR): 5 mg, PO , daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extensive Staging in Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
1. Patients undergoing examinations on suspicion of lung cancer (both SCLC and NSCLC) at St. Olavs Hospital~2. Potentially curable disease at the referral time (Stage I-III, based on the first CT)~3. Age ≥ 18 years~4. ECOG Performance 0-2~5. No serious concomitant disorders (for example marked reduced respiratory capacity, active infection, unstable cardiovascular disease, renal dysfunction) that in the opinion of the investigator would compromise the patient's ability to complete the study or interfere with the evaluation of the efficacy and safety of the study procedure~6. No contraindication for study specific procedure - bronchoscopy, CT, MRI and PET.~7. No conditions - medical, social, psychological - which could prevent adequate information and follow-up~8. No pregnancy or lactating women~9. Written informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard diagnostic work-up (Type: NO_INTERVENTION): All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.
- Extensive diagnostic work-up (Type: EXPERIMENTAL): All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Position May Reduce Acid Reflux Symptoms at Night

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between the ages of 18 and 65;~* Between 5'4 and 6'2~* Body Mass Index\<32~* Willing and able to provide written informed consent;~* Understands the clinical study requirements and is able to comply with the follow-up schedule set forth in the protocol;~* Clinically diagnosed with gastroesophageal reflux disease with extra-esophageal symptoms (i.e. chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing);~* Presents with Reflux Symptom Index (RSI) \> 13;~* Undergoing Esophagogastroduodenoscopy (EGD) as part of routine care;~* Undergoing 96-hour pH monitoring via BRAVO capsule as part of routine care.~Exclusion Criteria:~* Currently being treated with another investigational medical device and/or drug;~* Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP);~* Female patients who are of child-bearing potential and not using an acceptable method of birth control, or is pregnant or breast-feeding;~* Suspected esophageal cancer;~* Confirmed nasopharyngeal cancer;~* Previously undergone Nissen Fundoplication;~* Hiatal hernia \> 4 cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients with nocturnal extraesophageal reflux (Type: EXPERIMENTAL): This is a non-randomized study to evaluate the effectiveness of the MedclineTM Sleep Assist Device on patients who experience nocturnal extraesophageal reflux. All patients will receive the device. Participants will serve as their own controls while undergoing 96-hour pH monitoring. Participants will follow their regular sleep position patterns on Days 1 and 2 of the study and will use the sleep assist device on Days 3 and 4. pH data and patient report of symptoms will be evaluated during the initial 96 hours of the study to capture physiologic results. All participants will use the sleep assist device for the remainder of the study to determine if a reduction in overall reflux symptom index (RSI) is achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Long Term Effect of Adjustable Spaatz 3 Intragastric Balloon on Weight Loss

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- 1. Subjects willing to comply with study requirements and have signed an informed consent form.~2. Age 18-70 3. BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus 4. Documented negative pregnancy test in women of childbearing potential. 5. Women of childbearing potential agree to remain on contraceptives for the duration of their trial participation.~Exclusion Criteria:~* 1. Subjects receiving any prescription or over the counter weight loss medication within 30 days prior to randomization (including GLP-1 analogs).~  2. Previous GI surgery that could preclude the ability to place the device. 3. Subjects with a history of abnormal GI anatomical findings documented on imaging study, which in the opinion of the investigator, may impair implantation of the IGB device 4. Subjects with severe GERD that are not responding to Proton Pump Inhibitor (PPI) 5. Known abnormal pathologies or conditions of the upper gastrointestinal tract.~  6. Subjects with symptomatic gallstones within 6 months prior to randomization 7. Coagulopathy defined as hgb \<10g/dl and platelet \< 100,000/ml or diagnosis of hemophilia, factor X deficiencies or fibrinogen abnormalities 8. Subjects requiring prescription antithrombotic therapy (i.e. anticoagulant or antiplatelet agent) 9. Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) or any other drugs with bleeding as a potential side effect during the study duration.~  10. Subject is or has been enrolled in another investigational study within 3 months of participation into the current study 11. Subjects not residing within a 3 hour driving distance of the study center.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Spattz 3 intragastric balloon (Type: EXPERIMENTAL): obese patients, . BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus. All will have the intragastric balloon

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: InSeal Vascular Closure Device Clinical Study Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Candidate for large bore catheterization procedure (such as TAVI, aortic endograft repair) using a CE approved 18Fr access sheath.~* Subject age is at least 18 years~* Patient has signed most recent approved version of the Informed Consent~* Existence of an additional arterial access port is required in instances where an occluding balloon is planned to be used as a safety precaution.~Exclusion Criteria:~* Women Of Child Bearing Potential (WOCBP)~* Legally non-competent patients~* Patient participating in another clinical study at the time of the InSeal VCD study~* Prior target artery closure with a vascular closure device having intravascular component (such as Angio-Seal) 30 days prior to catheterization~* Subjects with known coagulopathy, preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the vessel access site prior to artery closure~* Patients that do not tolerate aspirin and clopidogrel anticoagulation treatment~* Prior vascular surgery or vascular graft in region of access site~* Significant calcification, atherosclerotic disease, or stent within 1.5 cm of the puncture site that may interfere with the operation of the experimental device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- InSeal's Vascular Closure Device (Type: EXPERIMENTAL): Use of the experimental VCD to close the access site of the artery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: LipiScan- Ultrasound INterrogation of Atherosclerotic Coronary Arteries:

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable ischemic heart disease or ACS undergoing cardiac catheterization and possible PCI of a culprit lesion~* The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent approved by the Institutional Review Board.~* The study patient agrees to comply with all required post-procedure follow up.~* Patient age 18-89 years old~Exclusion Criteria:~* STEMI within the prior 24 hours~* Cardiogenic shock or hypotension needing inotropes or hemodynamic support device~* Intra-procedural complication (perforation or a complication that would necessitate immediate-unplanned revascularization) during index PCI procedure~* History of CABG~* Subject life expectancy less than 2 years at time of index catheterization~* Pregnant or unknown pregnancy status~* Psychological unsuitability or extreme claustrophobia~* Currently participating in another investigational cardiac device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials~* Inability to tolerate beta blockers~* Atrio-ventricular block (grade II-III), prolonged QT interval or sick sinus syndrome~* Renal insufficiency (creatinine ≥ 1.6 and/or, GFR \< 60 ml/min) or renal failure requiring dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardiac Catheterization with NIRS/IVUS (Type: None): Cardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Currently pregnant~* The outcome of pregnancy (that is, pregnancy loss or live birth) must not be known at entry.~* Agrees to electronically sign the release of medical information form permitting the study to contact her HCPs (for example, primary care provider \[PCP\], obstetrician, nurse midwife) and the infant's HCP (for example, pediatrician) for medical information.~* Received the Moderna COVID-19 vaccine at any point from 28 days prior to last menstrual period (LMP) throughout pregnancy.~Exclusion Criteria:~* Participant has received any other COVID-19 vaccines at any point from 28 days prior to LMP throughout pregnancy.~* Women currently participating in another investigational device or drug study, currently taking an investigational medicinal product, or having taken an investigational product within 28 days prior to LMP or during pregnancy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Moderna COVID-19 Vaccine in Pregnant Women (Type: None): The Moderna COVID-19 Vaccine Pregnancy Registry will collect primary data from pregnant women who have received the Moderna COVID-19 vaccine and their healthcare providers (HCPs).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertension in use of renin-angiotensin system inhibitors~* Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical presentation and chest CT.~* Symptoms onset \< 96h~* Need for hospitalization~Exclusion Criteria:~* Heart failure~* Previous cerebrovascular disease~* Previous myocardial infarction~* Blood pressure \> 180 x 100 mmHg~* Need for 3 or more anti-hypertensive classes~* Use os spironolactone~* Severe pulmonary disease~* Contraindication for using other anti-hypertensive classes (calcium channel blockers, hydralazine, diuretics or nitrates)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Switch therapy (Type: EXPERIMENTAL): Renin-angiotensin system inhibitors will be changed for other anti-hypertensive classes.
- Maintenance therapy (Type: NO_INTERVENTION): Renin-angiotensin system inhibitors will be kept during in-hospital stay

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dilapan-S® for Induction of Labor The Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Planned induction of labor ≥ 39 weeks~2. Singleton gestation~3. Vertex presentation~4. Cervical dilation \<3cm~Exclusion Criteria:~1. Placenta previa~2. Placenta accreta~3. Vasa previa~4. Preterm prelabor rupture of membranes~5. Non-english speaking~6. \<18 years old~7. Multiple gestation~8. Prior cesarean delivery~9. Prior myomectomy~10. Fetal malpresentation~11. Active vaginal bleeding~12. Cervical dilation \>1 cm~13. Uterine anomaly (didelphysis, bicornuate)~14. Intrauterine growth restriction \<10th%~15. Fetal anomalies~16. Requirements to be inpatient~17. Polyhydramnios (AFI\>25cm or MVP\>8cm)~18. Chronic hypertension on medications~19. Gestational hypertension/preeclampsia~20. GDMA2, DM1, DM2~21. Hepatitis B or C~22. HIV

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dilapan S (Type: OTHER): Placement of dilators

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Over 18 years of age~* ER Negative and PR Negative~* Progression of disease in the metastatic setting despite taxane or other chemotherapeutic therapies including Herceptin (patients on Herceptin may continue this therapy while on study)~* Maximized chemotherapy in the metastatic setting or patient experienced side effects contributing to decreased quality of life and elects to defer chemotherapy~* Evaluable disease by either:~  * CT Scan with or without contrast (lesions must be greater than 2 mm)~ * PET Scan, or Bone Scan, or Plain skeletal films~ * Chest wall or skin recurrence (digital photo to capture evaluable disease)~* Evaluable symptoms (pain, shortness of breath, fatigue, anorexia)~* Performance Status of 0, 1, or 2~* Bilateral mammogram performed within one year before registration~Exclusion Criteria:~* Uncontrolled hypercalcemia greater than 11~* Uncontrolled congestive heart failure greater than 2 NYHA class~* Central Nervous System metastasis~* Concomitant steroid use~* Performance Status of greater than 2~* Bilirubin greater than 5.5

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues